|
Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients. |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Astellas Pharma; Prometheus |
Research Funding - Aragon Pharmaceuticals (Inst); GlaxoSmithKline (Inst); ImClone Systems (Inst); Janssen |
Travel, Accommodations, Expenses - Astellas Pharma |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Epic Sciences |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Patents Pending |
|
|
No Relationships to Disclose |